Major Recommendations shaping RD policy
The EU Committee of Experts on Rare Diseases (EUCERD, 2010-2013) and the European Commission Expert Group on Rare Diseases (CEG-RD, 2013-2016) were established to support EU policy on rare diseases, and specifically provide policy guidance on the effective implementation of the 2008 EU Commission Communication on Rare Diseases: Europe's challenges and the 2009 Council (of the European Union) Recommendation on action in the field of rare diseases.
The work of the EUCERD and CEG-RD was supported by the two EU Joint Actions for rare diseases, the EUCERD Joint Action (March 2012- November 2015) and RD-ACTION (June 2015- July 2018).
Membership
The EUCERD and CEG-RD brought together representatives from: the 28 EU Member States, Iceland, Norway, Switzerland, the EU Commission, the Committee for Orphan Medicinal Products of the EMA, industry, academia, eight individual experts as well as eight patient advocates, whose organisations are members of EURORDIS.
EURORDIS' involvement
These eight patient advocates (4 full members and 4 alternates) formed the EURORDIS Policy Action Group (PAG) and were assisted by two observers from the EURORDIS staff. They all attended each plenary meeting, EURORDIS covering the costs of alternates thereby ensuring a strong representation and voice of rare disease patients.
This group of patient advocates ensured that the patient perspective was reflected in all contributions and recommendations of the EUCERD and CEG-RD. They sought advice and opinions from the EURORDIS enlarged network where necessary.
Achievements: Adoption of Recommendations
The CEG-RD and EUCERD experts adopted by consensus the following recommendations and opinion. These recommendations are key in shaping current EU and national rare disease policies as they lay the foundations for the optimisation of care for rare disease patients, improved care pathways, patient registries and codifications for rare diseases:
Page created: 06/08/2010
Page last updated: 17/07/2018